What is the recommended acute management and treatment strategy for a patient with non‑ST‑segment elevation myocardial infarction (NSTEMI)?

Management of Non-ST-Segment Elevation Myocardial Infarction (NSTEMI)

All patients with NSTEMI should receive immediate dual antiplatelet therapy (aspirin plus a P2Y12 inhibitor) and parenteral anticoagulation, followed by risk stratification to determine timing of coronary angiography within 2–24 hours, with high-risk patients proceeding to early invasive strategy and revascularization. 1, 2

Immediate Medical Therapy (Start in Emergency Department)

Antiplatelet Therapy

• Aspirin: Administer 150–325 mg loading dose (non-enteric-coated, chewable preferred) immediately, followed by 75–100 mg daily indefinitely 1, 2
• P2Y12 Inhibitor: Start immediately before risk stratification 2
  • Ticagrelor (preferred): 180 mg loading dose, then 90 mg twice daily 1, 2
  • Prasugrel (alternative if undergoing PCI): 60 mg loading dose, then 10 mg daily (reduce to 5 mg daily if age ≥75 years or weight <60 kg) 1, 2
  • Clopidogrel (only if ticagrelor/prasugrel unavailable or contraindicated): 300–600 mg loading dose, then 75 mg daily 2, 3

Anticoagulation (Choose One)

• Fondaparinux (preferred for conservative management): 2.5 mg subcutaneous daily; favorable bleeding profile 2
• Enoxaparin (preferred if PCI planned and normal renal function): 1 mg/kg subcutaneous every 12 hours, or 30 mg IV bolus followed 15 minutes later by 1 mg/kg subcutaneous (no bolus if age >75 years) 2
• Unfractionated heparin (use if CABG anticipated within 24 hours or severe renal dysfunction): 60–70 U/kg IV bolus (maximum 5000 U), then 12–15 U/kg/h infusion (maximum 1000 U/h), target aPTT 1.5–2.5× control 1, 2
• Bivalirudin (alternative during PCI): 0.75 mg/kg IV bolus, then 1.75 mg/kg/h infusion 2

Additional Acute Therapies

• Oxygen: Only if SpO2 <90% or respiratory distress 1
• Nitroglycerin: Sublingual 0.4 mg every 5 minutes × 3 doses, then IV infusion if ongoing ischemia (contraindicated if systolic BP <90 mmHg, right ventricular infarction, or phosphodiesterase inhibitor use within 24–48 hours) 1
• Morphine: 2–4 mg IV for refractory chest pain unresponsive to nitrates 1
• Beta-blockers: Oral metoprolol 25–50 mg every 6–12 hours if no contraindications (avoid if heart failure, hemodynamic instability, heart block, or active bronchospasm) 2, 3

Risk Stratification and Timing of Invasive Strategy

Very High-Risk (Immediate Angiography <2 Hours)

• Hemodynamic instability or cardiogenic shock 2, 3
• Recurrent or refractory angina despite maximal medical therapy 1, 2
• Life-threatening ventricular arrhythmias or cardiac arrest 1, 2
• Mechanical complications (acute mitral regurgitation, ventricular septal defect, free wall rupture) 2
• Acute heart failure with pulmonary edema 1

High-Risk (Early Invasive Strategy 12–24 Hours)

• Dynamic ST-segment or T-wave changes (≥0.05 mV depression) 1, 2
• Elevated cardiac troponin 1, 2
• GRACE score >140 or TIMI score ≥3 2, 3
• Left ventricular ejection fraction <40% 1
• Prior PCI within 6 months or prior CABG 1

Intermediate-Risk (Invasive Strategy Within 24–72 Hours)

• Diabetes mellitus 1
• Renal insufficiency (eGFR <60 mL/min/1.73m²) 1
• GRACE score 109–140 2

Low-Risk (Conservative Strategy with Selective Angiography)

• No recurrent chest pain 1
• No heart failure 1
• Normal or minimally elevated troponin 1
• GRACE score <109 2
• No high-risk features on stress testing 1

Critical Evidence: The TACTICS-TIMI 18 trial demonstrated that early invasive strategy reduced death/MI/rehospitalization at 6 months (15.9% vs 19.4%; p=0.025) compared with conservative management 4. However, do not use routine upstream GP IIb/IIIa inhibitors before angiography—the EARLY-ACS trial showed this increases major bleeding (2.6% vs 1.8%; p=0.02) without reducing ischemic events 2.

Periprocedural Management for PCI

Before/During PCI

• Continue aspirin 1
• Administer P2Y12 inhibitor loading dose if not given earlier 1, 2
• GP IIb/IIIa inhibitor (eptifibatide, tirofiban, or abciximab) for high-risk patients with elevated troponin undergoing PCI 1
• Discontinue anticoagulation after uncomplicated PCI 2

Radial vs Femoral Access

• Radial approach preferred over femoral to reduce bleeding, vascular complications, and mortality 1

Complete vs Culprit-Only Revascularization

• Complete revascularization recommended in NSTEMI with multivessel disease; perform multivessel PCI either during index procedure or staged (single procedure preferred) 1

Management When CABG Is Planned

• Continue aspirin throughout perioperative period 1, 2
• Stop clopidogrel 5–7 days before surgery 1, 2
• Stop prasugrel at least 7 days before surgery 2
• Stop ticagrelor at least 5 days before surgery 2
• Stop GP IIb/IIIa inhibitors at least 4 hours before CABG 4
• Discontinue enoxaparin 12–24 hours before CABG 4
• Discontinue fondaparinux 24 hours before CABG 4
• Discontinue bivalirudin 3 hours before CABG and substitute UFH per institutional protocol 2, 4

Long-Term Management (Post-Discharge)

Dual Antiplatelet Therapy Duration

• Continue aspirin 75–100 mg daily indefinitely 1, 2
• Continue P2Y12 inhibitor for at least 12 months as default strategy 1, 2
• Ticagrelor monotherapy (discontinue aspirin) may be considered ≥1 month after PCI in patients who tolerated dual therapy, to reduce bleeding risk 1
• Consider extending dual antiplatelet therapy beyond 12 months only in very high ischemic risk patients with acceptable bleeding risk 2

Secondary Prevention

• High-intensity statin therapy for all patients 2, 3
• ACE inhibitor for heart failure, LV dysfunction (EF <40%), hypertension, or diabetes 2, 3
• Angiotensin receptor blocker (ARB) if ACE inhibitor intolerant 2, 3
• Beta-blocker for all patients without contraindications 2, 3
• Proton pump inhibitor for patients at risk of gastrointestinal bleeding 1
• Cardiac rehabilitation referral (home-based programs acceptable if unable to attend in person) 1
• Fasting lipid panel 4–8 weeks after initiating or adjusting lipid-lowering therapy 1

Absolute Contraindications to Specific Therapies

Do NOT Use Fibrinolytic Therapy

• Fibrinolysis is contraindicated in NSTEMI—meta-analyses show no benefit and increased risk of MI 1, 3

Do NOT Use NSAIDs (Except Aspirin)

• NSAIDs and COX-2 inhibitors increase death, reinfarction, and cardiac rupture; discontinue immediately 1, 3

Contraindications to Early Invasive Strategy

• Extensive comorbidities where procedural risk outweighs benefit (severe liver/pulmonary failure, active malignancy, terminal illness) 1, 4
• Patient refusal of revascularization 1, 4
• Low likelihood of ACS 1

Critical Pitfalls to Avoid

• Delaying angiography in high-risk patients worsens outcomes: ISAR-COOL trial showed 11.6% death/MI rate with delayed angiography (86 hours) versus 5.9% with early angiography (2.4 hours); p=0.04 4
• Do not withhold antiplatelet therapy until after angiography—start immediately upon diagnosis 4
• Do not give upstream GP IIb/IIIa inhibitors routinely—defer until catheterization unless refractory ischemia 2
• Do not rely solely on troponin elevation for risk stratification—use comprehensive clinical assessment including GRACE/TIMI scores 4
• Do not use lower aspirin maintenance doses during acute phase—81 mg daily is reasonable only after PCI 1